Enterotoxigenic Escherichia coli (ETEC) is the most common cause of diarrhea in children in developing countries and in travellers to these areas (1, 2) . It has been estimated that ETEC infections are responsible for at least 650 million cases of diarrhea, causing about 800,000 deaths each year in children below the age of 5 years (1) .
ETEC strains produce colonization factors (CFs), usually termed colonization factor antigens (CFAs), coli surface antigens (CS), or putative colonization factors (PCFs), that are responsible for attachment of the bacteria to the intestinal mucosa (11) . This binding is important to enable the bacteria to colonize and also to deliver heat-labile and/or heat-stable enterotoxins in close proximity to enterocytes. Production of specific secretory immunoglobulin A (IgA) antibodies against the CFs is very likely an important prerequisite for protection against ETEC disease (37) .
Effective vaccines against ETEC should probably consist of the most prevalent CFs in combination with an appropriate toxoid (37) . However, a major problem in the design of such a vaccine is the great number of antigenically heterogenic fimbrial adhesins. The best-characterized CFs are CFA/I (10) , CFA/II (9) , and CFA/IV (29) . CFA/I has a uniform fimbrial structure and is composed of one type of subunit (3) , whereas CFA/II-bearing strains may express one or two fimbriae, i.e., CS3 with or without CS1 or CS2 (36) , and CFA/IV strains express CS6 alone or in combination with fimbrial antigen CS4 or CS5 (29) . Several additional CFs have also recently been characterized, for example, CFA/III, PCFO159, PCFO166, CS7, CS17, PCFO9, and PCFO20 (13, 25, 26, 38, 40) . Furthermore, epidemiological studies indicate that a considerable portion of pathogenic ETEC strains do not express any of the hitherto characterized fimbriae (39) .
The ETEC fimbriae were originally shown to be antigenically distinct by using polyclonal antibodies and monoclonal antibodies (MAbs) against whole bacteria or purified whole fimbriae in, e.g., enzyme-linked immunosorbent assays (ELISA) and immunodiffusion techniques (28) . However, amino acid sequencing has shown very significant homology among several of the ETEC fimbriae; i.e., the N-terminal regions of CFA/I, CS1, CS2, CS4, PCFO166, and CS17 are very similar (15, 17, 19, 33) . In fact, immunological crossreactions between CFAII, CS1, CS2, CS4, and CS17 subunits have been revealed in immunoblotting experiments using polyclonal antisera raised against whole bacteria (27) . Furthermore, it was found that the cfaD gene that regulates the expression of CFA/I fimbriae can substitute for ins, which is required for production of CS1 and CS2 (4) , and it can also promote the production of CS4 fimbriae (41) . Immunological cross-reactions between CS5 and CS7 have also been observed in immunoblotting experiments (13) .
The different CFs are fimbriae, which may be either rod-like or helical structures about 6 to 8 nm in diameter or thinner, flexible, fibrillar structures (10, 21, 25, 29, 38, 42) . They are composed of protein subunits, each consisting of 147 to 200 amino acids, which results in a molecular size varying from 15 to 27 kDa (10, 21, 25, 29, 38, 42) . The structure of CFA/I fimbriae has been examined in detail, and it was found that only one type of CFA/I subunit exists (3). The subunit located at the fimbrial tip was shown to act as an adhesin, and a MAb against the CFA/I subunit proved to be a more effective inhibitor of hemagglutination (HA) than a MAb against whole CFA/I fimbriae (3). Mapping of the linear B-cell epitopes of the CFA/I subunit has located an immunodominant epitope at the N-terminal end (5) .
In this study, we produced MAbs against CFA/I subunits and examined whether these antibodies cross-react immunologically with other CFs. We also evaluated whether such MAbs can bind to a peptide corresponding to the N-terminal region of CFA/I and if they have the capacity to Hll ST'/LT+) and the corresponding CS7-mutant, 334C (13) .
All of the strains were grown on Casamino Acids-yeast extract agar (10) or, when appropriate, on Casamino Acidsyeast extract agar with bile salts (13) at 37°C overnight. Expression of type 1 fimbriae on the bacteria was excluded by testing for mannose-sensitive HA of guinea pig erythrocytes.
Fimbrial preparations. Purified CFA/I fimbriae were prepared from a flagellum-deficient mutant of strain H10407 (CFA/I+ 078:H-ST/LT) by homogenization with a blender (Waring, New Hartford, Conn.) followed by ammonium sulfate fractionation and negative DEAE-Sephadex column chromatography (10) . We purified CS4 fimbriae from strain E11881A (CS4+ CS6+ 025:H42 ST/LT) (29), CS5 fimbriae from strain E17018A (CS5+ CS6+ 0167:H5 ST+/LT-) (29) , and PCF 0166 fimbriae from strain E7476A by the methods described above. We prepared purified CS1 fimbriae from strain 60R936 and CS2 fimbriae from strain 58R957 by homogenization with an Ultra-Turrax T25 blender (Ica-Labortechnik) and then subjected them to ammonium sulfate fractionation and isopycnic cesium chloride gradient ultracentrifugation at 110,000 x g for 18 h (18) . The different strains were kindly provided by D. Evans (Houston, Tex.) or B. Rowe (London, England). The purity of fimbrial preparations was determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and Coomassie staining (PhastSystem; Pharmacia, Uppsala, Sweden) and also by immunoblotting with antisera against whole bacteria expressing the homologous fimbriae. The concentration of the fimbriae was determined by using a combination of the weight of a highly purified lyophilized reference preparation and the spectrophotometric A280-A310 value. New preparations were compared with the reference in an inhibition ELISA.
Dissociation of CFAII into subunits. Purified CFA/I fimbriae were dissociated into subunits by incubation in 6 and side chain-protected amino acids were from Nova Biochem. After synthesis, the peptide was cleaved from the resin and the protecting groups were removed from the amino acids by acidic hydrolysis using anisole and ethanedithiol (Merck, Darmstadt, Germany) as scavengers. Peptide composition was confirmed by amino acid analysis, and purity was assessed by reverse-phase high-pressure liquid chromatography.
Immunizations and production of specific antisera. Inbred female BALB/c mice, obtained from our breeding facilities, were used. After collection of preimmune serum, 6-week-old mice were immunized intraperitoneally with 5 jig of dissociated CFA/I or whole CFA/I fimbriae in complete Freund's adjuvant; 2 weeks later, 5 ,ug of the same antigen was given intraperitoneally in incomplete Freund's adjuvant. One week later, the mice were given 2.5 ,ug of the same antigen intravenously without adjuvant. Four days after the last immunization, the mice were killed by cervical dislocation, blood was drawn, and the spleens were excised. The antiserum was diluted 1/10 and absorbed twice with live bacteria and twice with boiled bacteria by using a CFA/I-deficient mutant of strain H10407, i.e., H10407P (CFA/1-078:H-ST/LT).
MAb production. Spleen lymphocytes were fused with cells of mouse myeloma cell-line P3x63-Ag8 653 (16) at a ratio of 1:2 by using polyethylene glycol (8) . The culture medium for selection of stable hybridoma cell lines contained hypoxanthine-aminopterin-thymidine in Iscove's medium (Biochrom KG, Berlin, Germany) with 10% fetal calf serum (Biochrom). After 10 days, the hybridomas were tested for production of specific antibodies against CFA/I fimbriae and CFA/I subunits by analyzing culture supernatants in the ELISA described below. The hybridomas producing the highest titers were propagated, and the supernatants were tested for reaction with purified fimbriae of CS1, CS2, CS4, PCFO166, and CS5 by using the ELISA and a dot blot test as described below. The hybridomas that reacted in the highest titers with heterologous CFAs were cloned by limiting dilution (12) , and stable hybridomas were expanded by cultivation first in 10 ml and then in 100 ml of 10% fetal calf serum-Iscove's medium devoid of antibiotics in tissue culture bottles (Nunc, Roskilde, Denmark). Culture fluids were harvested and frozen in aliquots at -30°C. In addition, MAb CS7 5:2, previously produced against whole purified fimbriae of CS7 (39) 
RESULTS
Production and reactivity of polyclonal antibodies. Sera from mice immunized with whole purified CFA/I fimbriae and isolated CFA/I subunits, respectively, were tested in an ELISA for reactivity with CFA/I fimbriae and subunits. Sera of mice immunized with CFA/I subunits had, as a mean, sevenfold higher antibody titers against both CFA/I subunits and fimbriae than did mice immunized with whole purified CFA/I fimbriae (Table 1) . In immunoblotting experiments, antisera from the different groups of mice were diluted to contain similar numbers of ELISA units against CFAII fimbriae, and the abilities of the two different antisera to bind to the different CFs, which were separated into subunits by SDS-PAGE, were compared. These analyses showed that serum raised against CFA/I subunits reacted more strongly with homologous, and also with heterologous, CFA subunits than did serum against whole purified CFAII fimbriae (Fig. 1) . As shown, antiserum against CFA/I subunits cross-reacted strongly with CS4 monomers and dimers and also, although less strongly, with CS1, PCFO166, CS17, and CS2. No reactivity with CS5 ( Fig. 1) , which lacks homology with the amino acid sequence of CFA/I (6, 15), was seen. MAb reactivity. The specific titers of the three different MAbs against CFAII fimbriae, CFA/I subunits, and the synthetic CFAII N-terminal peptide were determined in ELISAs. As shown in Table 2 , MAb S-CFA/I 17:8 reacted in a threefold higher titer with CFA/I subunits than with whole CFA/I fimbriae. This MAb also reacted strongly with the CFA/I peptide. MAb S-CFA/I 5:6 reacted somewhat better with CFA/I subunits than with CFAII fimbriae but did not react with the CFA/I peptide in the ELISA. MAb S-CFA/I 8:11, which reacted equally well with CFA/I fimbriae and CFA/I subunits, did not react with the peptide either.
The three different MAbs were also tested for reactivity with nitrocellulose-bound CF fimbriae, CF subunits, and the CFA/I peptide in dot blot experiments. As shown in Fig. 2A (Fig. 2B) . Both MAbs S-CFA/I 5:6 and S-CFA/I 8:11 bound more strongly to whole CFA/I fimbriae than did MAb S-CFAII 17:8. They also cross-reacted with CS1, CS2, PCFO166, and CS4 and cross-reacted weakly with CS17. None of the MAbs reacted with a CS5 fimbrial preparation which was used as a negative control.
The reactivities of MAbs S-CFA/I 17:8 and S-CFA/I 5:6 were also studied in immunoblotting experiments. As shown in Fig. 3A , MAb S-CFAII 17:8 cross-reacted with subunits of PCFO166, CS4, CS1, and CS2. MAb S-CFA/I 5:6 cross-reacted with subunits of PCFO166, CS1, CS2, CS4, and CS17 (Fig. 3B) HAI. Although peptide-binding MAb S-CFA/I 17:8 bound in a weaker fashion to whole CFA/I fimbriae than did the other two MAbs, it was the most effective of the MAbs at inhibiting HA by CFA/I-expressing bacteria (Fig. 4) . MAb S-CFA/I 5:6 was almost as effective at inhibiting CFA/I-positive bacteria, whereas MAb S-CFA/I 8:11 had a lower inhibitory titer. HAI by heterologous bacteria, especially CS1-and CS4-expressing strains, was almost as effective as that of homologous bacteria for both MAbs S-CFA/I 17:8 and S-CFA/I 5:6, whereas neither of these MAbs inhibited HA by CS7-expressing bacteria.
However, MAb S-CFA/I 8:11 did not inhibit HA of the heterologous strain expressing CS4. Neither did a MAb raised against CS7 fimbriae inhibit HA of CFA/I-positive bacteria. In the HAI experiments, we used a CS7-expressing strain and a MAb raised against purified CS7 fimbriae as negative controls, since we did not have access to a CS5-only strain. None of the three MAbs used agglutinated CFA/I-expressing bacteria. with MAb S-CFA/I 17:8 reduced binding to 9.6% ± 5. The anti-CFA/I subunit MAbs were also tested for the capacity to inhibit binding of bacteria expressing heterologous fimbriae. Inhibition of bacterial binding to Caco-2 cells was tested with bacteria expressing CS2, CS4, PCF0166, CS5, and CS7, since all of these fimbriae bind strongly to this cell line, whereas inhibition of binding of bacteria expressing CS1 and CS17 could not be tested, since these fimbriae do not bind to Caco-2 cells (38a). As shown in Fig. 6 The finding of stronger immune responses in serum both to CFA/I subunits and to CFA/I fimbriae after immunization with subunits than after immunization with whole fimbriae suggests that it may be advantageous to use protein subunits to elicit anti-CFA immunity. This effect is probably explained by more efficient antigen presentation in mice that were given subunits. There was not only a quantitative difference in immune responses against the subunits and the fimbriae, respectively, but also changes in epitope specificity regarding at least one epitope. Antiserum against isolated CFA/I subunits was shown to react with a peptide of 25 amino acids corresponding to the conserved N-terminal end of CFA/I, whereas antiserum against whole CFA/I fimbriae did not react with the peptide. A similar finding was recently reported by Cassels et al. (5), who mapped the linear B-cell epitopes of the CFA/I subunit by using antiserum raised in monkeys. Thus, results obtained from studies with both primates and, as shown in this study, mice indicate that an N-terminal epitope of CFA/I can be converted to immunodominance by immunization with isolated CFA/I subunits instead of whole CFA/I fimbriae.
It was recently shown that CFA/I fimbriae are composed of multiple identical protein subunits, each containing a receptorbinding site which is only exposed at the tip of the fimbria (3). This finding suggested that the probability of obtaining antibodies directed against epitopes close to the receptor-binding site might be improved by immunization with CFA/I subunits rather than with whole purified fimbriae. Moreover, immunologically cross-reactive antibodies might be more readily produced by immunization with CFA/I subunits rather than with whole purified fimbriae because of the exposure of conserved epitopes hidden in the quaternary structure. Although the immunodominant epitopes of the quaternary conformations of the various CFs are very different (28), we have previously shown that CFA/I fimbriae can both prime and boost the immune responses to CS4 and vice versa (34) , which indicates that conserved epitopes are exposed during degradation of the fimbriae in vivo. In the immunoblotting experiments of the present study, we found that an antiserum against the CFA/I subunits reacted more strongly with electrophoretically separated heterologous subunits than did an antiserum against whole fimbriae. Similarly, detailed studies of the fimbrial adhesins of uropathogenic E. coli species, e.g., those of P and S fimbriae, have shown that regions conserved among antigenically different fimbriae are often immunorecessive with regard to the polymeric structure of the intact fimbriae (14, 30) .
Nevertheless, these regions can be important because of involvement in the receptor-binding site.
The finding that one of the MAbs against CFA/I subunits, i.e., MAb S-CFA/I 17:8, cross-reacted strongly with the peptide corresponding to the N-terminal end of the CFA/I subunits was not unexpected, since the N-terminal regions of the subunit proteins of CFA/I, CS1, CS2, CS4, and PCF0166 have been shown to be very similar (19) . However, although the subunit protein of CS17 also appears to share considerable homology in the N-terminal end with these subunit proteins (19) , MAb S-CFA/I 17:8 did not bind to CS17 fimbriae. One possible explanation for this lack of reactivity may be that the minor differences in amino acid composition between CFA/I and CS17 result in different tertiary configurations of the two fimbriae or their subunits.
It was apparent from the ELISA 
